Veliparib in combination with carboplatin for the treatment of triple negative breast cancer

Scott H. Kaufmann, Anand G. Patel, Methods and materials for assessing responsiveness to parp inhibitors and platinating agents ,(2012)

Debdutta Bandyopadhyay, Mahitosh Mandal, Liana Adam, John Mendelsohn, Rakesh Kumar, Physical Interaction between Epidermal Growth Factor Receptor and DNA-dependent Protein Kinase in Mammalian Cells Journal of Biological Chemistry. ,vol. 273, pp. 1568- 1573 ,(1998) , 10.1074/JBC.273.3.1568

SJ Isakoff, S Pulhalla, SP Shepherd, N Falotico, B Kaufman, M Friedlander, M Robson, S Domchek, J Garber, E McKeegan, B Chyla, J Qian, VL Giranda, Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects withBRCA1orBRACA2mutation and metastatic breast cancer Cancer Research. ,vol. 72, ,(2012) , 10.1158/0008-5472.SABCS12-OT2-3-07

Laszlo Virag, Csaba Szabó, The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors Pharmacological Reviews. ,vol. 54, pp. 375- 429 ,(2002) , 10.1124/PR.54.3.375

Bassam S. Abdulkarim, Julie Cuartero, John Hanson, Jean Deschênes, David Lesniak, Siham Sabri, Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy Journal of Clinical Oncology. ,vol. 29, pp. 2852- 2858 ,(2011) , 10.1200/JCO.2010.33.4714

Shivaani Kummar, Robert Kinders, Martin E. Gutierrez, Larry Rubinstein, Ralph E. Parchment, Lawrence R. Phillips, Jiuping Ji, Anne Monks, Jennifer A. Low, Alice Chen, Anthony J. Murgo, Jerry Collins, Seth M. Steinberg, Helen Eliopoulos, Vincent L. Giranda, Gary Gordon, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski, James H. Doroshow, Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies Journal of Clinical Oncology. ,vol. 27, pp. 2705- 2711 ,(2009) , 10.1200/JCO.2008.19.7681

Rafael Santana-Davila, Edith A Perez, Treatment options for patients with triple-negative breast cancer Journal of Hematology & Oncology. ,vol. 3, pp. 42- 42 ,(2010) , 10.1186/1756-8722-3-42

A.M.M. Oonk, C. van Rijn, M.M. Smits, L. Mulder, N. Laddach, S.P. Savola, J. Wesseling, S. Rodenhuis, A.L.T. Imholz, E.H. Lips, Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy Annals of Oncology. ,vol. 23, pp. 2301- 2305 ,(2012) , 10.1093/ANNONC/MDR621

Cherrie K. Donawho, Yan Luo, Yanping Luo, Thomas D. Penning, Joy L. Bauch, Jennifer J. Bouska, Velitchka D. Bontcheva-Diaz, Bryan F. Cox, Theodore L. DeWeese, Larry E. Dillehay, Debra C. Ferguson, Nayereh S. Ghoreishi-Haack, David R. Grimm, Ran Guan, Edward K. Han, Rhonda R. Holley-Shanks, Boris Hristov, Kenneth B. Idler, Ken Jarvis, Eric F. Johnson, Lawrence R. Kleinberg, Vered Klinghofer, Loren M. Lasko, Xuesong Liu, Kennan C. Marsh, Thomas P. McGonigal, Jonathan A. Meulbroek, Amanda M. Olson, Joann P. Palma, Luis E. Rodriguez, Yan Shi, Jason A. Stavropoulos, Alan C. Tsurutani, Gui-Dong Zhu, Saul H. Rosenberg, Vincent L. Giranda, David J. Frost, ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models Clinical Cancer Research. ,vol. 13, pp. 2728- 2737 ,(2007) , 10.1158/1078-0432.CCR-06-3039

X.S. Chen, X.Q. Nie, C.M. Chen, J.Y. Wu, J. Wu, J.S. Lu, Z.M. Shao, Z.Z. Shen, K.W. Shen, Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer Annals of Oncology. ,vol. 21, pp. 961- 967 ,(2010) , 10.1093/ANNONC/MDQ041